Abstract
We report two cases of metastatic urothelial cancer treated with high-dose-intensity (HD) methotrexate vinblastine, doxorubicin and cisplatin (MVAC). After HD-MVAC, the size of primary and lymph node tumors decreased by 57-67% as compared with the standard M-VAC therapy. By shortening the dose interval, HD-MVAC may increase the anti-tumor effect without increasing side effects.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Neoplasms / secondary
-
Cisplatin / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Lung Neoplasms / secondary
-
Lymphatic Metastasis
-
Male
-
Methotrexate / administration & dosage
-
Neoplasm Staging
-
Pulse Therapy, Drug
-
Treatment Outcome
-
Ureteral Neoplasms / drug therapy*
-
Ureteral Neoplasms / pathology
-
Urinary Bladder Neoplasms / drug therapy*
-
Urinary Bladder Neoplasms / pathology
-
Vinblastine / administration & dosage
Substances
-
Vinblastine
-
Doxorubicin
-
Cisplatin
-
Methotrexate